Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)
General Information of Drug (ID: DR0813) | ||||||
---|---|---|---|---|---|---|
Drug Name |
Hydralazine hydrochloride
|
|||||
Synonyms |
Hydralazin; Hydralazinum; Hydrallazine; Hydrazinophthalazine; Hydrazone 1(2H)-phthalazinone; Hypophthalin; Idralazina; Idralazina [DCIT]; Idralazina [Italian]; hydralazine; phthalazin-1-ylhydrazine; (E)-1-Hydrazono-1,2-dihydrophthalazine; 1(2H)-Phthalazinone, hydrazone; 1-Hydrazinophthalazine; 1-Hydrazinylphthalazine; 1-Phthalazinylhydrazine; 59275-69-3; 6-Hydralazine; 86-54-4; Apresolin; Apressin; Apressin (pharmaceutical); Aprezolin; Ciba 5968; Hidralazin; Hidralazina; Hidralazina [Spanish]; Hipoftalin; Aiselazine; Apresoline hydrochloride; Dralzine; HYDRALAZINE HCL; HYDRALAZINE HYDROCHLORIDE; Hydralazine (hydrochloride); Hydralazine chloride; Hydralazine monohydrochloride; Hydrallazine hydrochloride; Hyperazin; Hyperex; Lopress; Praparat 5968; Slow-Apresolin; 1(2H)-Phthalazinone, hydrazone, hydrochloride; 1(2H)-Phthalazinone, hydrazone, monohydrochloride; 1-Hydrazinophthalazine hydrochloride; 1-Hydrazinophthalazine monohydrochloride; 1-Hydrazinylphthalazine hydrochloride; 304-20-1; CHEBI:31672
|
|||||
Indication | Essential hypertension [ICD11: BA00] | Approved | [1] | |||
Structure | ||||||
3D MOL is unavailable | 2D MOL | |||||
Pharmaceutical Properties | Molecular Weight | 196.64 | Topological Polar Surface Area | 63.8 | ||
Heavy Atom Count | 13 | Rotatable Bond Count | 1 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 4 | |||
Cross-matching ID | ||||||
The Metabolic Roadmap of This Drug | |||||
---|---|---|---|---|---|
The Full List of Drug Metabolites (DM) of This Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
References | ||||||
---|---|---|---|---|---|---|
1 | Hydralazine Hydrochloride was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration. | |||||
2 | N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 2017 Dec;45(12):1276-1281. | |||||
3 | Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther. 1981 May;29(5):588-93. | |||||
4 | Metabolism of hydralazine: relevance to drug-induced lupus | |||||
5 | Hypotensive effect of the hydralazine--acetone hydrazone in conscious rabbits: evidence for its back-conversion to hydralazine in vivo | |||||
6 | Pharmacokinetics and biotransformation of hydralazine acetone hydrazone, a metabolite of hydralazine, in the rat | |||||
7 | Quantitative analysis of hydralazine pyruvic acid hydrazone, the major plasma metabolite of hydralazine | |||||
8 | Hydralazine elimination in man | |||||
9 | DrugBank(Pharmacology-Metabolism):Hydralazine |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.